Clinicopathological features of early gastric cancer: Results of 100 casesfrom a rural general hospital

Objective: To evaluate 100 patients with early gastric cancer from the poin t of view of early detection, clinicopathological variables, and long term results. Design: Retrospective study. Setting: Rural general hospital, Japan. Subjects: 100 patients with early gastric cancer (confined to the epitheliu m, lamina propria, or submucosa) out of a total of 197 who had gastric canc ers resected for cure between May 1986 and April 1996. Interventions: Subtotal gastrectomy (n = 87), total gastrectomy (n = 8), pr oximal gastrectomy (n = 2), and local wedge resection (n = 3). Main outcome measures: Histopathological features and outcome. Results: The mean annual incidence of early gastric cancer was 51% (range 3 5%-70%). 16/59 patients with mucosal cancer (37%) and 18/41 with submucosal cancer (44%) presented with symptoms of the disease. The diagnosis was mad e in 62 by endoscopy, and in only 2 by upper gastrointestinal radiographic examination. None of the 59 with mucosal cancer had lymphatic invasion, and only 1 had a lymph node metastasis. Among the 41 with submucosal cancer, h owever, 15 had lymphatic invasion (37%), 13 had venous invasion (32%), and 2 had lymph node metastases (5%). 83 patients were alive with no sign of re currence at the time of writing (median follow up 62 months, range 12-136). One patient with a tumour that produced alpha-fetoprotein died of hepatic metastases 23 months after subtotal gastrectomy. 9 patients developed secon d cancers, and 6 died of these with no signs of recurrence of early gastric cancer. The overall 5 and 10 year survival rates were 82% and 66%, and the corresponding disease-specific survival rates for 85 patients were both 98 %. Conclusions: Excellent long term results can be achieved in the treatment o f early gastric cancer, even in a non-specialist centre. Patients with earl y gastric cancer should have their alpha-fetoprotein concentration measured , and be examined for the presence of other malignant disease both before a nd after treatment of the gastric cancer.